ClinicalTrials.gg
TerminatedNCT01661140Updated Oct 14, 2016Results posted

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

A Phase 4 interventional study of Methotrexate (stable dose) and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 67 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
17th of 113
427 · median 130
Started
2012
with 10 others
Phase 4
38 of 113
3 open now
Registered
66th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 11 that started in 2012, is one of 38 in phase 4, and was the 66th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate response to disease-modifying antirheumatic drugs (DMARDs) initiated on treatment with tocilizumab. Participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks and MTX orally weekly throughout the study. At Week 24, participants achieving a good/moderate EULAR response will be randomized receiving the MTX Tapering arm or MTX Maintenance arm. Up to Week 56 participants will receive either tapering or stable dose MTX in combination with tocilizumab. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Active severe rheumatoid arthritis (DAS28 > 5.1) according to European League of Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria
  • Inadequate response to a trial of 2 DMARDs, including methotrexate, a trial being defined as 6 months with 2 months at standard dose; no previous treatment with a biologic agent such as a tumor necrosis factor (TNF) inhibitor
  • Oral must have been at a stable dose of \</= 10 mg/day prednisolone or equivalent for at least 25 out of 28 days prior to start of treatment (Day 1)

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
  • Rheumatic disease other than rheumatoid arthritis
  • Functional class IV as defined by the ACR Classification of Functional Status in RA
  • Prior history of or current inflammatory joint disease other than RA
  • Previous treatment with tocilizumab
  • Previous treatment with any biologic drug (e.g. TNF inhibitor) that is used in the treatment of RA
  • Intraarticular or parenteral within 6 weeks prior to enrollment
  • Inadequate liver, bone marrow or hepatic function
  • Positive for , or infection
  • Pregnant or breastfeeding women
  • Females of who are not using reliable means of
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
  • Active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections
  • History of, or currently active, primary or secondary immunodeficiency
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    Methotrexate (MTX) Tapering Dosage

    At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.

    Drug: Tocilizumab · Drug: Methotrexate (tapering dose)

  • Active comparator
    Methotrexate (MTX) Maintenance Dosage

    At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.

    Drug: Methotrexate (stable dose) · Drug: Tocilizumab

Interventions

  • Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose

  • 8 mg/kg intravenously every 4 weeks for 72 weeks

    Also known as: RoActemra/Actemra

  • Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 60

    Response was determined using EULAR criteria based upon (Disease Activity Score In 28 Joints) DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\<=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'

    Time frame: From randomization to Week 60

Secondary outcomes

  1. Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 60

    The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Randomization (Week 24), Week 60

  2. Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72

    The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

    Time frame: Randomization (Week 24), Week 72

  3. Percentage of Participants Who Achieve Score of <=1 in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 60 and 72

    Percentage of participants who achieve score of =1 in TJC and SJC at week 60 and 72 were reported. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.

    Time frame: Week 60, 72

  4. Percentage of Participants Who Achieve a Disease Activity Score In 28 Joints (DAS28) <= 3.2

    The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve score \<=3.2 at weeks 60 and 72 were reported.

    Time frame: Week 60, 72

  5. Percentage of Participants Who Achieve DAS28 Remission (DAS28 < 2.6)

    The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve DAS28 remission score \<2.6 at weeks 60 and 72 were reported.

    Time frame: Week 60, 72

  6. Percentage of Participants Who Achieve Change in Disease Activity Score (cDAS) >=1.2

    The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve cDAS28 \>=1.2 score at weeks 60 and 72 were reported.

    Time frame: Week 60, 72

  7. Percentage of Participants Who Achieve Clinical Disease Activity Index (CDAI) Remission (CDAI < 2.8) at Week 60 and 72

    Clinical Disease Activity Index (CDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + patient global assessment of disease (PGA) 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity.

    Time frame: Randomization (Week 24), Week 60, 72

  8. Percentage of Participants Who Achieve Simplified Disease Activity Index (SDAI) Remission (SDAI < 3.3) at Week 60 and 72

    Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity.

    Time frame: Randomization (Week 24), Week 60, 72

  9. Percentage of Participants With Improvement in Physical Function Using Health Assessment Questionnaire [HAQ] at Week 60 and 72

    The HAQ-disability index (DI) evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of participants with an improvement in HAQ-DI score.

    Time frame: Randomization (Week 24), Week 60, 72

  10. Percentage of Participants With Improvement in Physical Function Using Functional Assessment of Chronic Illness Therapy - Fatigue [FACIT-F] at Week 60 and 72

    The FACIT-fatigue assessment was a 13-item questionnaire with participants scoring each item on a 5-point scale (not at all; a little bit; somewhat; quite a bit and very much). The total score ranges from 0 to 65 and higher scores indicate more fatigue. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in total FACIT score.

    Time frame: Randomization (Week 24), Week 60, 72

  11. Percentage of Participants With Improvement in Physical Function Using 12-item Short Form Health Survey [SF-12]) at Week 60 and 72

    Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in SF-12 score.

    Time frame: Randomization (Week 24), Week 60, 72

  12. Percentage of Participants With Anemia

    Time frame: Week 0 up to Week 72

  13. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any adverse event that can be fatal, life threatening, requires long or prolong hospitalization, results in persistent or significant disability/incapacity, congenital anomaly or significant medical event in the investigator's judgment.

    Time frame: Week 0 up to Week 72

  14. Percentage of Participants Able to Discontinue Methotrexate

    Time frame: Week 0 up to Week 60

  15. Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)

    The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities.

    Time frame: Randomization (Week 24), Week 60, 72

  16. Hours Actually Worked and Work Hours Missed Assessed Using the WPAI-SHP

    The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Reported here are hours actually worked, work hours missed due to rheumatoid arthritis (RA), work hours missed due to other reasons and the change from Week 24 for each of these parameters reported at Week 60 and Week 72.

    Time frame: Randomization (Week 24), Week 60, Week 72

  17. Change in Productivity and Regular Daily Activities Affected by Rheumatoid Arthritis Assessed Using the WPAI-SHP

    The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Assessments were made using a visual analogue scale ranging from 0 to 10 where 0 = minimum impact and 10 = maximum impact.

    Time frame: Randomization (Week 24), Week 60, 72

07

Results

Posted Oct 14, 2016

Participant flow

Open-Label Period
Participant flow — Open-Label Period
MilestoneInitial PhaseMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Started42700
Completed35100
Not completed7600
Withdrew: Adverse event4400
Withdrew: Protocol violation300
Withdrew: Withdrawal by subject500
Withdrew: Investigator decision300
Withdrew: Death100
Withdrew: Administrative/other100
Withdrew: Sponsor termination1600
Withdrew: Did not meet eular criteria100
Withdrew: Lost to follow-up200
Double-Blind Period
Participant flow — Double-Blind Period
MilestoneInitial PhaseMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Started0136136
Completed09586
Not completed04150
Withdrew: Refused treatment001
Withdrew: Adverse event01618
Withdrew: Protocol violation023
Withdrew: Withdrawal by subject013
Withdrew: Investigator's decision012
Withdrew: Sponsor termination01417
Withdrew: Administrative/other076

Outcome measures

PrimaryPercentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 60

Response was determined using EULAR criteria based upon (Disease Activity Score In 28 Joints) DAS28 absolute scores at the assessment visit and the DAS28 reduction from the reference visit. Participants with a score lesser than or equal to (\<=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \<=5.1 with reduction of \>0.6 to \<=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \<=1.2 points, or any score with reduction \<=0.6 points, were assessed as non-responders with response recorded as 'none.'

Time frame:
From randomization to Week 60
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 60
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Percentage of Participants Maintaining Previous Disease Activity (European League Against Rheumatism [EULAR] Response) From Week 24 (Time of Randomization) to Week 6076.565.4
Statistical analysis
  • Methotrexate (MTX) Tapering Group vs Methotrexate (MTX) Maintenance Group · Analysis by logistic regression · p = 0.036 · Odds ratio (or): 1.803 · 95% CI 1.037 to 3.133
SecondaryChange From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 60

The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Randomization (Week 24), Week 60
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 60
units on a scaleMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Baseline (n= 135, 136)2.572 ± 1.32182.573 ± 1.3017
Change at Week 60 (n= 134, 135)-0.179 ± 1.1702-0.233 ± 1.5156
SecondaryChange From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72

The DAS28 defined as a combined index for measuring disease activity in rheumatoid arthritis (RA). The index included swollen (range 0-28) and tender joint counts (TJC) (range 0-28), acute phase response Erythrocyte Sedimentation Rate (ESR), and general health status (range 1-100). The index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.

Time frame:
Randomization (Week 24), Week 72
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72
units on a scaleMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Change From Baseline in Disease Activity Score In 28 Joints (DAS28) Score at Week 72-0.105 ± 1.2262-0.224 ± 1.4961
SecondaryPercentage of Participants Who Achieve Score of <=1 in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 60 and 72

Percentage of participants who achieve score of =1 in TJC and SJC at week 60 and 72 were reported. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.

Time frame:
Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Score of <=1 in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
TJC <=1, Week 6039.039.0
SJC <=1, Week 6044.158.1
TJC <=1, Week 7237.540.4
SJC <=1, Week 7255.960.3
SecondaryPercentage of Participants Who Achieve a Disease Activity Score In 28 Joints (DAS28) <= 3.2

The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve score \<=3.2 at weeks 60 and 72 were reported.

Time frame:
Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Disease Activity Score In 28 Joints (DAS28) <= 3.2
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 6059.662.5
Week 7261.060.3
SecondaryPercentage of Participants Who Achieve DAS28 Remission (DAS28 < 2.6)

The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve DAS28 remission score \<2.6 at weeks 60 and 72 were reported.

Time frame:
Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve DAS28 Remission (DAS28 < 2.6)
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 6051.547.1
Week 7250.051.5
SecondaryPercentage of Participants Who Achieve Change in Disease Activity Score (cDAS) >=1.2

The DAS28 index was calculated using the following formula: The DAS28 was calculated as \[0.28 x the square root of number of swollen joints\] + \[0.56 x the square root of number of tender joints\] + \[0.7 x the natural log of ESR\] + \[0.014 x patient global assessment of disease activity\]. Participants who achieve cDAS28 \>=1.2 score at weeks 60 and 72 were reported.

Time frame:
Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Change in Disease Activity Score (cDAS) >=1.2
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 609.616.2
Week 729.615.4
SecondaryPercentage of Participants Who Achieve Clinical Disease Activity Index (CDAI) Remission (CDAI < 2.8) at Week 60 and 72

Clinical Disease Activity Index (CDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + patient global assessment of disease (PGA) 10 centimeter \[cm\] Visual Analog Scale \[VAS\] + physician global assessment of disease (PhGA) 10 cm VAS. VAS assessments involved a 10 cm horizontal scale from 'no disease activity' to 'maximum disease activity.' CDAI scores ranged from 0 to 76, with higher scores indicating increased disease activity.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Disease Activity Index (CDAI) Remission (CDAI < 2.8) at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 602.91.5
Week 721.53.7
SecondaryPercentage of Participants Who Achieve Simplified Disease Activity Index (SDAI) Remission (SDAI < 3.3) at Week 60 and 72

Simplified Disease Activity Index (SDAI) was an index for measuring disease activity in RA. The index was calculated using the following formula: CDAI: SJC28 + TJC28 + PGA (10 cm VAS) + PhGA (10 cm VAS + C-Reactive Protein (CRP). VAS assessments involved a 10-cm horizontal scale from 'no disease activity' to 'maximum disease activity. Scores ranged from 0 to 86, with higher scores also indicating increased disease activity.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Simplified Disease Activity Index (SDAI) Remission (SDAI < 3.3) at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 602.90.7
Week 722.90.7
SecondaryPercentage of Participants With Improvement in Physical Function Using Health Assessment Questionnaire [HAQ] at Week 60 and 72

The HAQ-disability index (DI) evaluates participant-reported quality of life using 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities such as running errands and performing household chores and 20 questions. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of participants with an improvement in HAQ-DI score.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in Physical Function Using Health Assessment Questionnaire [HAQ] at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Improvement at Week 6027.039.6
Improvement at Week 7240.550.0
SecondaryPercentage of Participants With Improvement in Physical Function Using Functional Assessment of Chronic Illness Therapy - Fatigue [FACIT-F] at Week 60 and 72

The FACIT-fatigue assessment was a 13-item questionnaire with participants scoring each item on a 5-point scale (not at all; a little bit; somewhat; quite a bit and very much). The total score ranges from 0 to 65 and higher scores indicate more fatigue. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in total FACIT score.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in Physical Function Using Functional Assessment of Chronic Illness Therapy - Fatigue [FACIT-F] at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Improvement at Week 6054.050.0
Improvement at Week 7245.256.3
SecondaryPercentage of Participants With Improvement in Physical Function Using 12-item Short Form Health Survey [SF-12]) at Week 60 and 72

Quality of life questionnaire (SF-12) scores were computed using the scores of 12 questions and ranged from 0 to 100, where a 0 score indicated the lowest level of health measured by the scales and 100 indicated the highest level of health. Improvement was defined as a decrease from Week 24 to Week 60 and 72. Reported is the percentage of subjects with an improvement in SF-12 score.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement in Physical Function Using 12-item Short Form Health Survey [SF-12]) at Week 60 and 72
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Improvement at Week 6022.210.4
Improvement at Week 7223.815.6
SecondaryPercentage of Participants With Anemia
Time frame:
Week 0 up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Anemia
percentage of participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Percentage of Participants With Anemia1.50.7
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was any adverse event that can be fatal, life threatening, requires long or prolong hospitalization, results in persistent or significant disability/incapacity, congenital anomaly or significant medical event in the investigator's judgment.

Time frame:
Week 0 up to Week 72
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
AEs9898
SAEs93
SecondaryPercentage of Participants Able to Discontinue Methotrexate
Time frame:
Week 0 up to Week 60

No measurements were reported for this outcome.

SecondaryNumber of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)

The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Number · participants
Number of Subjects Employed Assessed Using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)
participantsMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Week 603317
Week 722314
SecondaryHours Actually Worked and Work Hours Missed Assessed Using the WPAI-SHP

The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Reported here are hours actually worked, work hours missed due to rheumatoid arthritis (RA), work hours missed due to other reasons and the change from Week 24 for each of these parameters reported at Week 60 and Week 72.

Time frame:
Randomization (Week 24), Week 60, Week 72
Reported as:
Median · hours
Hours Actually Worked and Work Hours Missed Assessed Using the WPAI-SHP
hoursMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Hours actually worked (HAW), Week 60 (n=33, 17)25.0 (0 to 58)28.0 (0 to 40)
Change from Week 24 in HAW, Week 60 (n=29, 17)-1.0 (-47 to 40)2.0 (-43 to 38)
Work hours missed (WHM) to RA, Week 60 (n=33, 17)0.0 (0 to 15)0.0 (0 to 35)
Change from Week 24 in WHM RA, Week 60 (n=30, 16)0.0 (-30 to 15)0.0 (-7 to 21)
WHM other, Week 60 (n=33, 17)0.0 (0 to 46)0.0 (0 to 35)
Change from Week 24 WHM other, Week 60 (n=30, 16)0.0 (-56 to 46)0.0 (-38 to 35)
HAW, Week 72 (n=23, 13)30.0 (0 to 48)16.0 (0 to 40)
Change from Week 24 in HAW, Week 72, (n=20, 12)0.0 (-37 to 23)2.5 (-30 to 40)
WHM to RA, Week 72 (n=23, 13)0.0 (0 to 37)0.0 (0 to 35)
Change from Week 24 in WHM RA, Week 72 (n=21, 11)0.0 (-30 to 37)0.0 (-7 to 21)
WHM other, Week 72 (n=23, 13)0.0 (0 to 30)0.0 (0 to 8)
Change from Week 24 WHM other, Week 72 (n=21, 11)0.0 (-56 to 30)0.0 (-38 to 2)
SecondaryChange in Productivity and Regular Daily Activities Affected by Rheumatoid Arthritis Assessed Using the WPAI-SHP

The WPAI-SHP questionnaire assesses work productivity and activity impairment. It is a patient-reported assessment regarding hours missed and hours worked at employment and degree to which a specified health problem affected work productivity and regular activities. It consists of 6 questions to assess the impact of a specific health problem on work productivity and on regular daily activities. Assessments were made using a visual analogue scale ranging from 0 to 10 where 0 = minimum impact and 10 = maximum impact.

Time frame:
Randomization (Week 24), Week 60, 72
Reported as:
Median · units on a scale
Change in Productivity and Regular Daily Activities Affected by Rheumatoid Arthritis Assessed Using the WPAI-SHP
units on a scaleMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
Productivity (P), Week 60 (n=34, 18)2.0 (0 to 8)2.0 (0 to 10)
Change in P from Week 24 at Week 60 (n=30, 16)1.0 (-6 to 8)0.0 (-5 to 7)
Regular Daily Activities (RDA), Week 60 (n=60, 45)3.0 (0 to 9)3.0 (0 to 9)
Change in RDA from Week 24 at Week 60 (n=59, 44)0.0 (-5 to 7)0.0 (-6 to 6)
Productivity (P), Week 72 (n=24, 12)3.0 (0 to 8)3.0 (0 to 9)
Change in P from Week 24 at Week 72 (n=21, 11)0.0 (-3 to 4)0.0 (-5 to 7)
Regular Daily Activities (RDA), Week 72 (n=42, 31)3.0 (0 to 10)3.0 (0 to 9)
Change in RDA from Week 24 at Week 72 (n=41, 29)0.0 (-5 to 4)-1.0 (-5 to 7)

Adverse events

Collected over From start of treatment to unscheduled visit (up to Week 72). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Phase—21/427 (4.9%)263/427 (61.6%)
Methotrexate (MTX) Tapering Group—9/136 (6.6%)62/136 (45.6%)
Methotrexate (MTX) Maintenance Group—3/136 (2.2%)70/136 (51.5%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventInitial PhaseMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
DiverticulitisInfections and infestations0/4272/1360/136
PneumoniaInfections and infestations2/4272/1360/136
Abdominal SepsisInfections and infestations0/4271/1360/136
Bursitis InfectiveInfections and infestations0/4270/1361/136
Lymph Node TuberculosisInfections and infestations0/4270/1361/136
Necrotising FasciitisInfections and infestations0/4271/1360/136
Device DislocationGeneral disorders0/4271/1360/136
Ankle FractureInjury, poisoning and procedural complications0/4271/1360/136
Joint DislocationInjury, poisoning and procedural complications0/4271/1360/136
Back PainMusculoskeletal and connective tissue disorders0/4271/1360/136
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInitial PhaseMethotrexate (MTX) Tapering GroupMethotrexate (MTX) Maintenance Group
NasopharyngitisInfections and infestations61/42716/13617/136
DiarrhoeaGastrointestinal disorders54/4277/13611/136
Alanine Aminotransferase IncreasedInvestigations51/4276/1367/136
Mouth UlcerationGastrointestinal disorders48/4275/1369/136
Lower Respiratory Tract InfectionInfections and infestations41/42711/13612/136
HeadacheNervous system disorders38/4278/1366/136
Upper Respiratory Tract InfectionInfections and infestations23/42712/1367/136
RashSkin and subcutaneous tissue disorders32/4273/1367/136
CoughRespiratory, thoracic and mediastinal disorders29/4278/1366/136
Urinary Tract InfectionInfections and infestations19/4279/1366/136

Baseline characteristics

Age, Continuous
Age, Continuous(years)Initial Phase
Mean55.0 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)Initial Phase
Female326
Male101
08

Study locations

67 sites
  • Aberdeen, AB25 2ZN, United Kingdom
  • Abergavenny, NP7 7EG, United Kingdom
  • Ashford, TW15 3AA, United Kingdom
  • Aylesbury, HP21 8AL, United Kingdom
  • Barnsley, S75 2EP, United Kingdom
  • Basingstoke, RG24 9NA, United Kingdom
  • Bournemouth, BH23 2JX, United Kingdom
  • Brighton, BN2 5BE, United Kingdom
  • Bury St Edmonds, IP33 2QZ, United Kingdom
  • Cambridge, CB2 2QQ, United Kingdom
  • Cannock, WS11 5XY, United Kingdom
  • Cardiff, CF14 4XW, United Kingdom
  • Chelmsford, CM1 7ET, United Kingdom
  • Chester, CH2 1UL, United Kingdom
  • Coventry, CV2 2DX, United Kingdom
  • Crewe, CW1 4QJ, United Kingdom
  • Darlington, DL3 6HX, United Kingdom
  • Derby, DE22 3NE, United Kingdom
  • Dudley, DY1 2HQ, United Kingdom
  • Dundee, DD12 9SY, United Kingdom
  • Eastbourne, BN21 2UD, United Kingdom
  • Exeter, EX2 5DW, United Kingdom
  • Gillingham, ME7 5NY, United Kingdom
  • Greenock, PA16 0XN, United Kingdom
  • Guildford, GU2 7XX, United Kingdom
  • Harrogate, HG2 7SX, United Kingdom
  • Hull, HU3 3JZ, United Kingdom
  • Isle of Wight, PO30 5TG, United Kingdom
  • Leeds, LS7 4SA, United Kingdom
  • Liverpool, L9 7AL, United Kingdom
  • Llantrisant, CF72 8XR, United Kingdom
  • Londonderry, BT47 6SB, United Kingdom
  • London, E11 1NR, United Kingdom
  • London, SE18 4QH, United Kingdom
  • London, SW17 0QT, United Kingdom
  • London, W6 8RF, United Kingdom
  • Maidstone, ME16 9QQ, United Kingdom
  • Manchester, M13 9PT, United Kingdom
  • Manchester, M41 5SL, United Kingdom
  • Middlesborough, TS4 3BW, United Kingdom
  • North Shields, NE29 8NH, United Kingdom
  • Northampton, NN1 5BD, United Kingdom
  • Nottingham, NG7 2UH, United Kingdom
  • Oldham, OL1 1NL, United Kingdom
  • Plymouth, PL6 8DH, United Kingdom
  • Reading, RG1 5AN, United Kingdom
  • Salford, M6 8HD, United Kingdom
  • Salisbury, SP2 8BJ, United Kingdom
  • Sheffield, S10 2JF, United Kingdom
  • Somerset, TA1 5DA, United Kingdom
  • Southampton, SO16 6YD, United Kingdom
  • Southport, PR8 6PN, United Kingdom
  • Stevenage, SG1 4AB, United Kingdom
  • Stoke-on-trent, ST6 7AG, United Kingdom
  • Sunderland, SR4 7TP, United Kingdom
  • Sutton in Ashfield, NG17 4JL, United Kingdom
  • Swindon, SN3 6BB, United Kingdom
  • Torquay, TQ2 7AA, United Kingdom
  • Truro, TR1 3LJ, United Kingdom
  • Walsall, WS2 9PS, United Kingdom
  • Warwick, CV34 5BW, United Kingdom
  • Westcliffe-on-sea, SS0 0RY, United Kingdom
  • Wirral, CH49 5PE, United Kingdom
  • Wolverhampton, WV10 0QP, United Kingdom
  • Worthing, BN11 2DH, United Kingdom
  • Wrightington, WN6 9EP, United Kingdom
  • York, YO31 8HE, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2012
First posted
Aug 9, 2012
Start
Sep 2012
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Oct 14, 2016
Last update
Oct 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01661140
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 9, 2012
Start date
Sep 2012
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Oct 14, 2016
Last update
Oct 14, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion